Physiotherapy Approach for Susac Syndrome

April 4, 2024 updated by: Darko Bilic, Rehabilitation Centre Zivot

Integrated Physiotherapy Approach for Susac Syndrome: A Comprehensive Case Study

Susac's syndrome is a rare autoimmune disorder characterised by a triad of encephalopathy (brain dysfunction), branch retinal artery occlusion (loss of vision) and sensorineural hearing loss. This study presents the case of a patient undergoing intensive physiotherapy intervention following an injury, focusing on assessments such as volume and range of motion measurements, manual muscle tests, and pain intensity evaluations using various scales.

Study Overview

Status

Completed

Conditions

Detailed Description

The patient, aged 17, initially presented with severe limitations in mobility, diagnosed with Susac syndrome. Requiring assistance to walk even short distances due to fear and insecurity. Through a structured physiotherapy program spanning several months, various assessments were conducted, including manual muscle tests and circumference measurements. Significant improvements were observed for muscle function, upper and lower limb circumferences, and performance in mobility tests.

Study Type

Observational

Enrollment (Actual)

1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The study population consisted of a single adolescent patient diagnosed with Susac syndrome, aged 17 years. The patient presented with motor impairments and functional limitations attributed to Susac syndrome, including difficulties in mobility and muscle weakness. No significant comorbidities were reported, and the patient was medically stable to participate in a 12-week intensive physiotherapy program. Informed consent was obtained from the participant and their legal guardian prior to enrollment in the study."

Description

Inclusion Criteria:

  • Confirmed diagnosis of Susac syndrome.
  • Willingness and ability to participate in a 12-week intensive physiotherapy program.
  • Stable medical condition that allows participation in physiotherapy without significant risks.
  • Ability to provide informed consent for participation in the study.

Exclusion Criteria:

  • Presence of severe comorbidities or medical conditions that would interfere with participation in physiotherapy or confound the study outcomes.
  • Inability to comprehend or follow the instructions for physiotherapy exercises.
  • Pregnancy, as certain physiotherapy modalities may not be suitable during pregnancy.
  • Any other condition or circumstance that, in the opinion of the investigator, would compromise the safety or validity of participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mobility and Muscle Strength Improvement
Time Frame: Assessed at baseline and after 12 weeks of intensive therapy.
This outcome measure evaluates improvements in mobility in a single individual with Susac syndrome following 12 weeks of intensive physiotherapy. Assessments include the Timed Up and Go test (TUG), which measures the time taken for the individual to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. Progress is indicated by the transition from heavy reliance on assistance for mobility to independent walking for 100 meters.
Assessed at baseline and after 12 weeks of intensive therapy.
Muscle Strength Improvement Outcome Measure
Time Frame: Assessed at baseline and after 12 weeks of intensive therapy.
This outcome measure evaluates improvements in muscle strength in a single individual with Susac syndrome following 12 weeks of intensive physiotherapy. Assessments include manual muscle tests (MMT) to assess the strength and function of specific muscle groups, using a standardized grading scale. Progress is indicated by higher grades in manual muscle tests, reflecting improved muscle strength and endurance.
Assessed at baseline and after 12 weeks of intensive therapy.
Pain Intensity Outcome Measure
Time Frame: Assessed at baseline and after 12 weeks of intensive therapy.
This outcome measure evaluates changes in pain intensity experienced by the individual with Susac syndrome following 12 weeks of intensive physiotherapy. Pain intensity is assessed using the Visual Analog Scale (VAS), where the individual rates their pain on a scale from 0 to 10, with 0 indicating no pain and 10 indicating the worst possible pain. Progress is indicated by a decrease in VAS scores, reflecting reduced pain intensity.
Assessed at baseline and after 12 weeks of intensive therapy.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rehabilitation Centre Zivot

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 13, 2023

Primary Completion (Actual)

April 1, 2023

Study Completion (Actual)

April 6, 2023

Study Registration Dates

First Submitted

March 29, 2024

First Submitted That Met QC Criteria

April 4, 2024

First Posted (Actual)

April 5, 2024

Study Record Updates

Last Update Posted (Actual)

April 5, 2024

Last Update Submitted That Met QC Criteria

April 4, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Susac Syndrome

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe